Treatment Options for Age-Related Macular Degeneration
For wet (neovascular) AMD, intravitreal anti-VEGF injections are the definitive treatment, while for dry AMD with geographic atrophy, complement inhibitors (pegcetacoplan or avacincaptad pegol) are now FDA-approved options, and AREDS2 supplementation should be used for intermediate disease to slow progression.
Wet (Neovascular) AMD Management
First-Line Treatment: Anti-VEGF Therapy
Anti-VEGF intravitreal injections remain the gold standard for choroidal neovascularization (CNV) 1, 2. Available agents include:
- Bevacizumab (Avastin) - full-length monoclonal antibody binding all VEGF isoforms 1
- Ranibizumab - validated in ANCHOR study for predominantly classic CNV 1
- Aflibercept
- Brolucizumab
- Faricimab 2
Dosing Regimens
The treat-and-extend regimen demonstrates superior outcomes compared to fixed or PRN (pro-re-nata) dosing 2. This approach maximizes therapeutic benefit while optimizing treatment burden. The CATT trial established that individualized PRN dosing can be compared against monthly injections, but treat-and-extend has emerged as the preferred strategy 1.
Treatment Goals
Focus on preventing severe visual loss (defined as quadrupling of visual angle, e.g., 20/20 to 20/80 or worse) 1. Early detection of metamorphopsia using Amsler grid testing enables timely intervention 1.
Dry AMD Management
Geographic Atrophy (Advanced Dry AMD)
Two FDA-approved complement inhibitors are now available in the United States 2, 3:
- Pegcetacoplan - targets C3 protein in complement cascade
- Avacincaptad pegol - targets C5 protein in complement cascade
Both are administered via intravitreal injection and have demonstrated phase 3 evidence for reducing geographic atrophy growth 2, 4.
Intermediate AMD
AREDS2 supplementation is the evidence-based intervention for intermediate disease 1. The formulation includes:
- High-dose macular xanthophylls (lutein and zeaxanthin)
- Omega-3 long-chain polyunsaturated fatty acids (DHA and EPA)
- Modified zinc levels (lower than original AREDS)
- Beta-carotene can be deleted from the formulation 1
This supplementation slows progression to advanced AMD based on the prospective, multicenter AREDS2 trial involving 4,000 participants 1.
Risk Factor Modification
Modifiable risk factors must be aggressively addressed 2, 5:
- Smoking cessation - single most important modifiable factor
- Mediterranean-style diet - protective dietary pattern
- Hypertension control - cardiovascular optimization
- Regular exercise - systemic health maintenance
Monitoring Strategy
Patients require Amsler grid home monitoring to detect early metamorphopsia 1. Any sudden distortion or vision loss demands urgent ophthalmology referral for possible neovascular conversion 5.
For wet AMD patients on anti-VEGF therapy, optical coherence tomography angiography (OCTA) enables detailed characterization of MNV subtypes (types 1,2, and 3) through depth-resolved imaging 6. In geographic atrophy, OCTA assists in identifying subclinical MNV and assessing choriocapillaris perfusion in peri-atrophic zones 6.
Emerging Therapies
Sustained-release implants and hydrogel platforms for drug delivery are under investigation 2. Gene therapy and stem cell therapy represent the most promising future pathways for both dry and neovascular AMD 2, 7.
For non-exudative MNV (particularly type 1 and type 3 lesions), OCTA provides prognostic information regarding risk of exudative conversion 6.
Critical Pitfalls
Do not delay anti-VEGF treatment in wet AMD - the window for visual recovery narrows rapidly with subfoveal CNV 1. Do not assume all fluid is neovascular - OCTA helps differentiate pseudovitelliform lesions and exclude neovascularization in atypical presentations 6. Do not overlook AREDS2 supplementation in intermediate disease - this is the only proven intervention to slow progression before advanced stages develop 1, 5.